1. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients
- Author
-
F. Boulerice, Jean-Guy Baril, Richard G. Lalonde, Mona Loutfy, Cécile Tremblay, John S. Sampalis, Anita Rachlis, and Benoit Trottier
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Pyridines ,Atazanavir Sulfate ,HIV Infections ,Internal medicine ,Antiretroviral Therapy, Highly Active ,medicine ,Humans ,Pharmacology (medical) ,Atazanavir/ritonavir ,Aged ,Retrospective Studies ,Ritonavir ,business.industry ,Cholesterol, HDL ,Retrospective cohort study ,Cholesterol, LDL ,HIV Protease Inhibitors ,Middle Aged ,Discontinuation ,Surgery ,Atazanavir ,CD4 Lymphocyte Count ,Regimen ,Infectious Diseases ,RNA, Viral ,Female ,business ,human activities ,Viral load ,Oligopeptides ,medicine.drug - Abstract
To describe the durability of treatment, virological and immunological response, and safety of an atazanavir/ritonavir (ATV/RTV)-based highly active antiretroviral therapy (HAART) regimen in treatment-naïve HIV-infected patients.This was a multicentre retrospective study. Medical charts of antiretroviral-na'i've HIV-infected adults who initiated ATV/RTV (300/100 mg) from January 2004 to December 2007 in 10 Canadian clinics were reviewed. Data were collected from time of ATV/RTV treatment initiation until discontinuation of ATV. Durability of treatment and time to virological response were estimated with Kaplan-Meier functions. Change in viral load, CD4 cell counts, and lipid parameters were assessed with linear regression analyses.176 patients were enrolled, 153 (86.9%) were male, and the majority (52.3%) were 40 to 54 years old. Duration of observation ranged from 1.6 to 56 months. The mean (SE) durability of treatment was 33.5 (0.7) months. There were 37 (21.0%) patients who discontinued ATV/ RTV, among whom 18 (10.2%) discontinued due to toxicity, suboptimal virological response, loss to follow-up, or death. The mean (SE) time to HIV viral load of50 and400 copies/mL was 6.6 (0.4) and 4.3 (0.3) months, respectively. At 96 weeks of treatment, least squares mean (LSM) estimated change in log10(HIV copies/mL) was -2.94 (P.001) and +245 cells/mL (P.001) for CD4 cell count. A significant LSM increase in HDL-C of 0.24 mmol/L (P = .007 for trend over time) was also observed; total cholesterol, triglycerides, and LDL-C increased over time but their change did not reach statistical significance. The most frequently reported adverse event was increased bilirubin (16.5%).ATV/RTV-based first-line HAART regimen demonstrated durability and effectiveness and was well tolerated in treatment-naïve HIV-infected patients.
- Published
- 2011